Stocktoria
CRYO CELL INTERNATIONAL INC CCEL
NYSE American · XASE · stock · Services-Misc Health & Allied Services, NEC · website · IPO 1994-04-04
CRYO CELL INTERNATIONAL INC financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.6M | $32.0M | $31.3M | $30.3M | $28.9M | $31.1M | $31.8M | $29.2M | $25.4M | $23.1M |
| R&D expense | $376,263 | $1.2M | $1.2M | $384,789 | $49,870 | $23,851 | $30,145 | $91,845 | $41,165 | $53,097 |
| SG&A expense | $18.2M | $18.5M | $17.2M | $15.6M | $14.6M | $14.3M | $14.9M | $15.6M | $13.5M | $14.7M |
| Operating income | $482,394 | $3.5M | -$12.3M | $4.0M | $4.0M | $7.7M | $5.1M | $5.2M | $5.0M | $433,594 |
| Interest expense | $2.1M | $1.9M | $1.2M | $1.5M | $1.4M | $1.5M | $1.7M | $1.5M | $1.3M | $947,340 |
| Income tax | $92,232 | $2.4M | -$3.8M | $547,540 | $527,710 | $1.4M | $1.1M | $4.5M | $1.3M | -$1.2M |
| Net income | -$2.4M | $402,095 | -$9.5M | $2.8M | $2.1M | $3.6M | $2.3M | -$854,824 | $2.3M | -$1.3M |
| EPS (diluted) | $-0.30 | $0.05 | $-1.14 | $0.33 | $0.25 | $0.45 | $0.27 | $-0.11 | $0.30 | $-0.16 |
| Operating cash flow | $5.5M | $6.0M | $8.9M | $8.6M | $7.9M | $8.5M | $6.3M | $5.3M | $5.7M | $5.0M |
| Free cash flow | $5.2M | $3.6M | $2.1M | -$3.6M | $6.1M | $8.4M | $5.6M | $4.9M | $5.6M | $4.6M |
| Cash & equivalents | $319,031 | $560,960 | $406,067 | $1.7M | $8.3M | $10.4M | $6.5M | $6.0M | $6.3M | $3.5M |
| Inventory | $408,794 | $657,703 | $768,877 | $851,230 | $921,213 | $927,318 | $1.1M | $1.3M | $314,566 | $361,142 |
| Total assets | $61.7M | $64.7M | $64.7M | $64.9M | $60.7M | $46.2M | $42.9M | $42.9M | $23.9M | $19.5M |
| Total liabilities | $80.3M | $77.9M | $72.3M | $66.4M | $56.5M | $48.9M | $49.8M | $51.3M | $36.4M | $35.0M |
| Shareholders' equity | -$18.6M | -$13.2M | -$11.0M | -$1.5M | $4.2M | -$2.7M | -$7.0M | -$8.9M | -$12.5M | -$15.4M |
Growth · year-over-year · Revenue CAGR 3.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -1.3% | +2.0% | +3.3% | +5.0% | -7.3% | -2.1% | +8.9% | +15.1% | +9.8% | +9.7% |
| Net income growth | -704.2% | — | -443.6% | +33.0% | -42.5% | +58.2% | — | -136.9% | — | -116.3% |
| EPS growth | -700.0% | — | -445.5% | +32.0% | -44.4% | +66.7% | — | -136.7% | — | -119.3% |
| Free cash flow growth | +45.5% | +73.4% | — | -159.0% | -27.2% | +48.5% | +15.3% | -13.0% | +21.0% | -2.1% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0000862692 · as of 2025-11-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.